Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiphospholipid syndrome: an evolving story.

Beverley Robertson1, Mike Greaves

  • 1Department of Haematology, Aberdeen Royal Infirmary, ABERDEEN, AB25 2ZN, Scotland, UK. beverley.robertson@nhs.net

Blood Reviews
|January 31, 2006
PubMed
Summary

Antiphospholipid Syndrome (APS) involves immune-mediated thrombophilia and pregnancy issues, diagnosed by antiphospholipid antibodies (APA). Standard anticoagulation manages most venous thrombosis, but optimal treatment for arterial thrombosis and fetal loss requires further research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Red blood cell mannoses as phagocytic ligands mediating both sickle cell anaemia and malaria resistance.

Nature communications·2021
Same author

The chequered history of the antiphospholipid syndrome.

British journal of haematology·2014
Same author

Antiphospholipid syndrome: unusual clinical presentations.

Thrombosis research·2011
Same author

SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage.

Blood·2010
Same author

Clinical guidelines for testing for heritable thrombophilia.

British journal of haematology·2010
Same author

Pathogenesis and management of antiphospholipid syndrome.

Thrombosis research·2009

Area of Science:

  • Immunology
  • Hematology
  • Obstetrics and Gynecology

Background:

  • Antiphospholipid Syndrome (APS) is an immune-mediated thrombophilia characterized by recurrent thrombosis and pregnancy morbidity.
  • Diagnosis relies on detecting antiphospholipid antibodies (APA), such as Lupus Anticoagulant (LA) or anticardiolipin antibodies (ACA).
  • The pathophysiology suggests prothrombotic antibody activity and multifactorial thrombosis mechanisms.

Purpose of the Study:

  • To review the clinical presentations, diagnostic challenges, and management strategies for Antiphospholipid Syndrome (APS).
  • To evaluate the efficacy of anticoagulation in managing thrombotic and obstetric complications of APS.
  • To identify areas requiring further research in APS management, particularly for recurrent thrombosis and fetal loss.

Main Methods:

Related Experiment Videos

  • Review of existing literature and randomized controlled trials (RCTs) on Antiphospholipid Syndrome (APS).
  • Analysis of data regarding anticoagulation therapy for venous and arterial thrombosis in APS.
  • Assessment of studies on obstetric complications and management options in APS.

Main Results:

  • Standard intensity anticoagulation is effective for most venous thrombosis cases in APS.
  • The optimal intensity and duration of anticoagulation for recurrent or arterial thrombosis remain under investigation.
  • The management of recurrent fetal loss in APS is debated, with ongoing research into the benefits of heparin and aspirin versus aspirin alone.

Conclusions:

  • Anticoagulation is the primary treatment for APS-related thrombotic and obstetric complications.
  • Further research is needed to determine optimal anticoagulation strategies for arterial thrombosis and recurrent fetal loss in APS patients.
  • Standard anticoagulation appears adequate for most venous thrombotic events, but high-intensity therapy requires further evaluation.